Alex Hillenbrand

A cross-sectional study indicates a link between urinary levels of measured metals and metalloids and the stages of cardiovascular-kidney-metabolic syndrome.

A retrospective observational cohort study identifies an association between patients undergoing peritoneal dialysis and their physical activity level.

A retrospective cohort study developed and validated a predictive model for IgA nephropathy, using routinely available variables.

A meta-epidemiologic study highlights barriers to inclusion of older adults undergoing maintenance dialysis in randomized controlled trials.

A review of 32 years of global data on FSGS highlights increased prevalence, with a limitation of biopsy variation and regional practices.

Cross-sectional analysis from NHANES shows patients with advanced cardiovascular-kidney-metabolic syndrome are at an increased sarcopenia risk.

FDA approves zoliflodacin (Nuzolvence) for uncomplicated gonorrhea, offering a new oral treatment amid rising antibiotic resistance.

Weight-adjusted waist index outperforms obesity indices for cardiovascular disease prediction in cardiovascular-kidney-metabolic syndrome

Findings comparing kidney-after-liver to simultaneous transplant highlight similarities in allograft survival outcomes, but notable eGFR differences.

VTL-308 post-hoc analysis shows corticosteroids may decrease AKI risk in severe alcohol-associated hepatitis, but don’t affect recovery.

In women with CKD, there are no general survival advantages compared to the male patient population.

A retrospective cohort in finerenone showed nearly 40% proteinuria reduction at 8 months and stable eGFR in patients with IgA nephropathy.

A longitudinal cohort study shows a lack of correlation between decreased proteinuria levels and improved treatment, renal responses in patients.

Decreased serum albumin levels can be a tool for predicting the risk of cancer and mortality in patients undergoing hemodialysis.

Findings suggest people with reduced kidney function have higher levels of Alzheimer’s biomarkers in their blood but not an increased risk of dementia.

A single-center retrospective survey urges clinicians to address recurrent urinary tract infections in kidney transplant recipients.

Findings from a meta-analysis show peritoneal dialysis might preserve cognitive function compared to hemodialysis in chronic kidney disease.

In a cross-sectional OCTA analysis of patients with referable diabetic retinopathy, CKD emerges as an independent predictor of higher MA burden.

A multicenter study outlines stage-specific risk factors, protective traits for sarcopenia in older adults on maintenance hemodialysis, supporting earlier screening.

Key FDA approvals, pivotal IgAN and glomerular trial results, and transplant and CKD insights from November 2025.

A competing mortality-risk model improves calibration and captures more true 5-year kidney failure events.

Meta-analysis shows semaglutide lowers cardiovascular and kidney risks while supporting safety in adults with chronic kidney disease.

International registry analysis highlights consistent outcomes, calls for global collaboration in managing high-risk post-transplant pregnancies.

Patients with MASLD, advanced CKM stages face higher mortality and liver fibrosis, emphasizing the need for early risk assessment.

Pediatric IgA nephropathy shows slow progression, high remission rates, and frequent relapse, with new risk factors identified to improve long-term prognosis and management.

Bariatric surgery, particularly sleeve gastrectomy, may improve survival and kidney transplant access in older adults with obesity and ESKD.

Phase 3 trial shows MIL62 accelerates remission, reduces relapse risk, and improves kidney function compared with cyclosporine A in adults with primary MN.

Non-RASi antihypertensive use before pregnancy in women with IgAN increased the risk of severe HDP and preterm delivery.

Dual BLyS/APRIL inhibition with telitacicept led to significant 24h-UPCR reductions, lower progression-risk thresholds, and stable eGFR compared with placebo.

The FDA adds a boxed warning to delandistrogene moxeparvovec-rokl (ELEVIDYS) restricting indications to ambulatory patients with DMD.